128 related articles for article (PubMed ID: 22255596)
41. Network based consensus gene signatures for biomarker discovery in breast cancer.
Fröhlich H
PLoS One; 2011; 6(10):e25364. PubMed ID: 22046239
[TBL] [Abstract][Full Text] [Related]
42. Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining.
Song XC; Fu G; Yang X; Jiang Z; Wang Y; Zhou GW
Mol Cell Proteomics; 2008 Jan; 7(1):163-9. PubMed ID: 17934210
[TBL] [Abstract][Full Text] [Related]
43. Construction of robust prognostic predictors by using projective adaptive resonance theory as a gene filtering method.
Takahashi H; Kobayashi T; Honda H
Bioinformatics; 2005 Jan; 21(2):179-86. PubMed ID: 15308545
[TBL] [Abstract][Full Text] [Related]
44. Integration of clinical and microarray data with kernel methods.
Daemen A; Gevaert O; De Moor B
Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():5411-5. PubMed ID: 18003232
[TBL] [Abstract][Full Text] [Related]
45. Developing a novel test to detect cancer genes from microarray data.
Mathur S; Mathur S
Int J Bioinform Res Appl; 2014; 10(6):628-46. PubMed ID: 25335567
[TBL] [Abstract][Full Text] [Related]
46. Derivation of a fifteen gene prognostic panel for six cancers.
Khirade MF; Lal G; Bapat SA
Sci Rep; 2015 Aug; 5():13248. PubMed ID: 26272668
[TBL] [Abstract][Full Text] [Related]
47. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
48. Detecting common gene expression patterns in multiple cancer outcome entities.
Yang X; Bentink S; Spang R
Biomed Microdevices; 2005 Sep; 7(3):247-51. PubMed ID: 16133813
[TBL] [Abstract][Full Text] [Related]
49. Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks.
Gevaert O; De Smet F; Timmerman D; Moreau Y; De Moor B
Bioinformatics; 2006 Jul; 22(14):e184-90. PubMed ID: 16873470
[TBL] [Abstract][Full Text] [Related]
50. CAERUS: predicting CAncER oUtcomeS using relationship between protein structural information, protein networks, gene expression data, and mutation data.
Zhang KX; Ouellette BF
PLoS Comput Biol; 2011 Mar; 7(3):e1001114. PubMed ID: 21483478
[TBL] [Abstract][Full Text] [Related]
51. Male infertility biomarkers and genomic aberrations in azoospermia.
Kovac JR; Lamb DJ
Fertil Steril; 2014 May; 101(5):e31. PubMed ID: 24680367
[No Abstract] [Full Text] [Related]
52. Prognostic gene signatures for patient stratification in breast cancer: accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions.
Cun Y; Fröhlich HF
BMC Bioinformatics; 2012 May; 13():69. PubMed ID: 22548963
[TBL] [Abstract][Full Text] [Related]
53. Screening of Prognostic Factors in Early-Onset Breast Cancer.
Yu Z; He Q; Xu G
Technol Cancer Res Treat; 2020; 19():1533033819893670. PubMed ID: 32028860
[TBL] [Abstract][Full Text] [Related]
54. A method for predicting disease subtypes in presence of misclassification among training samples using gene expression: application to human breast cancer.
Zhang W; Rekaya R; Bertrand K
Bioinformatics; 2006 Feb; 22(3):317-25. PubMed ID: 16267079
[TBL] [Abstract][Full Text] [Related]
55. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
56. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
57. Antibody microarray analysis of the serum proteome in primary breast cancer patients.
Böhm D; Keller K; Boehm N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
Cancer Biol Ther; 2011 Nov; 12(9):772-9. PubMed ID: 21885915
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
59. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
60. BioPlat: a software for human cancer biomarker discovery.
Butti MD; Chanfreau H; Martinez D; García D; Lacunza E; Abba MC
Bioinformatics; 2014 Jun; 30(12):1782-4. PubMed ID: 24574115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
